Biocon Biologics to buy biosimilars business of Viatris for up to $3.3bn
Biocon Biologics Limited (BBL), a subsidiary of Indian biopharma company Biocon, has agreed to acquire the biosimilars business of Viatris, a US-based pharma company, in ... Read More
Biocon ties-up with Tabuk to bring specialty generic products in Middle East
Indian pharma company Biocon Limited has forged a partnership with Tabuk Pharmaceutical Manufacturing Company to commercialize certain specialty generic medicines in the Middle East. Tabuk ... Read More
Biocon Biologics, Viatris launch interchangeable biosimilars in US
Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine ... Read More
Biocon to sell 15% stake in Biocon Biologics to Serum Institute of India
Biocon has agreed to divest a stake of around 15% in its subsidiary — Biocon Biologics Limited (BBL) to Serum Institute Life Sciences Private Limited ... Read More
Biocon gets license for Adagio Therapeutics’ ADG20 for Covid-19 treatment
Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing ... Read More
Biocon, Libbs Farmaceutica team up for launching generic drugs in Brazil
Biocon Ltd, an Indian biopharma company, has entered into a partnership with Brazilian pharma company Libbs Farmaceutica for launching generic drugs in Brazil. The company ... Read More
Biocon expands generics portfolio with Tacrolimus launch in US
Biocon, the prominent Indian biopharmaceutical company, has made a significant leap in the US pharmaceutical market with the launch of its generic Tacrolimus capsules. This ... Read More